|  |
| --- |
| BIOGRAPHICAL SKETCH |
|  |
| NAMEArgyrios TzouvelekisPersonal DetailsArgyrios Tzouvelekis | POSITION TITLEProfessor of Respiratory Medicine/Head of Department of Respiratory Medicine, University of Patras, Greece, Associate Professor Adjunct of Respiratory Medicine, Yale School of Medicine, USAFather’s Name: EvangelosMother’s Name: MariannaDOB: 1st April 1980 (01/04/80)Εmail: argyris.tzouvelekis@gmail.comargyrios.tzouvelekis@fleming.gratzouvelekis@upatras.grORCID ID: <https://orcid.org/0000-0002-6295-1384>SCOPUS ID: 8898879100AD SCIENTIFIC INDEX ID: 4325902Medical Licence: 1869/29-07-2003Work Address: University Hospital of Patras, 26504, GreeceFacebook: Argyris Tzouvelekis, Twitter: @atzouvelekis, Linkedin: Argyris Tzouvelekis |
| EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)* |
| INSTITUTION AND LOCATION | DEGREE*(if applicable)* | YEAR(s) | FIELD OF STUDY |
| University of Crete School of Medicine, Greece | MD | 1997-2003 | Medicine |
| Democritus University of Thrace, Medical School, Greece | PhD |  2004-2008  | Role of Hypoxia Inducible Factor 1a in the pathogenesis of Idiopathic Pulmonary Fibrosis |
| Medical School, Democritus University of Thrace  | MSc | 2009-2011 | Clinical Pharmacology and Therapeutics |
| Yale School of Medicine, Section of Pulmonary Critical and Sleep Medicine, New Haven, USA | Post-doctoral | 2013-2016 | Phosphatases-Thyroid Hormone in IPF |
| Biomedical Sciences Research Center Alexander Fleming, Athens, Greece | Post-doctoral | 2016-2018 | Phosphatases-Kinases in IPF |
| 1ST Academic Dpt of Pneumonology, Hospital of Thoracic Diseases “Sotiria”, University of Athens, Greece | Consultant Physician/Clinical Scholar | 2017-present | IPF - ILDs |
| Associate Professor of Internal and Respiratory Medicine, University of Patras, Greece  | Faculty | 2019 - present | Medicine |
| European Respiratory Society Executive Officer | Internal Auditor | 2019 - present | Medicine |
| Associate Professor Adjunct Respiratory Medicine, Yale School of Medicine, USA | Faculty | 2021-present | Medicine |

1. **Personal Statement**

**Education and clinical accomplishments:** **I am Professor of Internal and Respiratory Medicine at the University of Patras, Greece and Head of the Department of Respiratory Medicine at the University Hospital of Patras, Greece as well as Associate Professor Adjunct at Pulmonary Critical Care and Sleep Medicine Department, Yale School of Medicine, USA.**

**From 2019 – 2022 I was also an Executive Officer-Internal Auditor of European Respiratory Society and since 2018 i serve as a member of the European Respiratory Society (ERS) College of Experts, official reviewer of ERS fellowships and Awards, mentor of ERS young scientists (ERS mentoring scheme), Associate Editor of Respiratory Research and Frontiers in Medicine. I am the head of the ERS Task Force on IPF and Lung cancer. I enumerate 267 publications in Scopus and 250 in PubMed with 7713 citations and H-index 48 ( 31% as first author, 23% as last author, and 46% as middle author).**

**My professional career is as follows:** In 2003, I graduated from the School of Medicine, University of Crete, Greece. From 2004-2008, Dr. Tzouvelekis successfully completed his PhD studies with grade of “excellence” in the Medical School, Democritus University of Thrace. In 2004, I was granted with the European Respiratory Society Long Term Research Fellowship and worked up to October 2005 as a research fellow in the Interstitial Lung Disease Unit, Imperial College, Royal Brompton and Harefield Hospital, London, where I was specialized in the genotypic analysis of patients with different forms of interstitial lung diseases. From 2007 to 2012, I successfully completed with excellence my rotation in the Departments of Pneumonology, Internal and Critical Care Medicine, Medical School at Democritus University of Thrace, Greece. Throughout my rotation, I have performed over 5000 flexible bronchoscopic, including more than 500 endobronchial ultrasound (EBUS) procedures and more than 100 rigid port thoracoscopic procedures. In July 2011, I extended my skills of expertise in the area of clinical pharmacology and i was granted with excellence, a master (MSc) of Clinical Pharmacology and Therapeutics. In 2012, i successfully took the exams and was awarded the HERMES European Respiratory Diplomat in recognition of my clinical skills and knowledge on a European level. I successfully completed my obligatory military services between September 2012 and May 2013. In October of 2013 I was awarded a fully-funded post-doctoral position at the Department of Internal Medicine, Section of Critical Care and Sleep Medicine, Yale School of Medicine, CT, USA under the supervision of Professor Naftali Kaminski and the financial support of American Lung Association. In January 2017 I was granted a fully-sponsored position as a Consultant Respiratory Physician at the First Academic Respiratory Department of the General Hospital for Thoracic Diseases “SOTIRIA”, Athens, Greece. In May 2018 I became a certified performer of Endobronchial Ultrasound Bronchoscopy further extending my skills in interventional pulmonology beyond conventional bronchoscopy and medical thoracoscopy. I am a member of the Hellenic Thoracic, European Respiratory and the American Thoracic Society. I am also reviewer in several journals including: American Journal of Respiratory and Critical Care Medicine, Annals of American Thoracic Society, Respiration, Respiratory Research, Respiratory Medicine, Respirology, BMC Pulmonary Medicine, Thorax. I am associate Editor ***of Frontiers in Medicine***, indexed in Pubmed,-IF: 5.1- peer-reviewed journal (<http://journal.frontiersin.org/researchtopic/5234/pulmonary-fibrosis>) and Respiratory Research. I am an official instructor in two Master degree programs at the Democritus University of Thrace, and one at the National and Kapodistrian University of Athens, Greece (1-Master of Clinical Pharmacology and Therapeutics, 2-Master of Sleep Medicine, 3- Master in Mechanisms of Respiratory Failure). In September of 2017 I became member of the ERS College of Experts and was assigned full responsibilities as a reviewer of ERS Fellowships and Awards. I am also an active member of the ERS RESPIRE mentoring scheme and was assigned responsibilities as a mentor of young scientists awarded by ERS fellowships. **I am also Principal Investigator in 45 clinical studies conducted at the Department of Respiratory Medicine, University of Patras Greece.**

**Research accomplishments:** My research focus is the mechanisms and treatment of pulmonary fibrosis, centering on the role of hypoxia, phosphatases and thyroid hormone signaling in the pathogenesis of lung fibrosis. I was trained in major aspects of translational medicine, including genomics and proteomics, as well as in molecular and cellular fibroblast biology using advanced methodological tools, including microarray and miRNA platforms, nCounter (Nanostring) technology and animal models of lung fibrosis (ie bleomycin-induced). My specialties are focused on the implementation of pioneering research technologies, such as microarrays, as well as the application of novel therapeutic interventions including stem cells. I currently enumerate **271 publications in Scopus and 254 in Pubmed** in peer-reviewed scientific journals (with an overall of **7713 citations** and a total **H-index=48-Scopus, ( 31% as first author, 23% as last author, and 46% as middle author).** , more than 100 presentations and lectures in national and international conferences and **30 grants** and honors, including **a) European Respiratory Society Long Term Research Fellowship and b) European Respiratory Society-Young Scientist Sponsorship and c) American Lung Association Senior Research Training Fellowship, d) an European Respiratory Society/Marie Skłodowska-Curie Postdoctoral Research Fellowship. I am currently the chairman of the ERS CPG-TF on the management of patients with IPF -Lung cancer. My major research accomplishments are summarized below:**

1. **Inventor of two therapeutic patents entitled a) “Inhaled or aerosolized delivery of thyroid hormone to the lung as a novel therapeutic agent in fibrotic lung diseases” OCR#6368 (the “Invention”) b) “ A method of preventing or treating a fibrotic lung disease in a subject comprising administering to the subject a thyroid receptor b-agonist. The invention further comprises compositions and kits comprising compositions useful within the invention 2023/0372275, disclosed to Yale University**. During my 3-year post-doctoral training I focused on the role of **thyroid hormone** signaling in the pathogenesis and treatment of Idiopathic Pulmonary Fibrosis (IPF). I identified that aerosolized Thyroid Hormone exerts therapeutic effects in two models of experimental lung fibrosis through a mechanism that involves enhancement of mitochondrial function in alveolar epithelial cells. **The manuscript, in which I am shared first author, has been published in *Nature Medicine* *2018 Jan;24(1):39-49* (IF: 53.4, Citations 154)**
2. **Identification of a phosphatase (SHP2) as a potent anti-fibrotic regulator in pulmonary fibrosis.** Another major project while at Yale University was to delineate the role of a ubiquitously expressed phosphataseSHP2 (SH2 domain-containing-tyrosine phosphatase) as a therapeutic target in Idiopathic Pulmonary Fibrosis (IPF). I discovered that SHP2 is master regulator of fibroblast homeostasis through mechanisms that involve negative regulation of pro-fibrotic signal transduction pathways and induction of autophagy in lung fibroblasts. I aspire to formulate a small molecule (SHP2 activator) and explore its therapeutic efficacy in experimental models of lung fibrosis. The project was published in the ***Am J Respir Crit Care Med* *2017 Feb 15;195(4):500-514*, IF:30.5 Citations: 41, followed by an editorial by Downey et al-** ***doi:***[***10.1164/rccm.201609-1921ED***](https://doi.org/10.1164/rccm.201609-1921ED)***.***
3. **Implication of a major transcription factor (HIF-1a) in the pathogenesis of lung fibrosis.** In this original contribution, I applied sophisticated experimental procedures by using DNA and tissue microarray technology in both human and animal samples and demonstrated that Hypoxia Inducible Factor (HIF-1a) was one of the most upregulated genes in the bleomycin model of lung fibrosis. Results were further extended by immunolocalization studies showing that HIF-1a was upregulated within the alveolar epithelium and co-localized with apoptotic target genes (p-53) in IPF lung samples. Results were published in the ***Am J Respir Crit Care Med* *2007 Dec 1;176(11):1108-19*, IF:30.5, Citations:148**
4. **Principal investigator of the first worldwide stem cell clinical trial in patients with Idiopathic Pulmonary Fibrosis** This study showed for the first time in literature that endobronchial infusion of adipose derived stem cells is safe and deserves further attention in the context of large multicenter clinical trials. To this end, results of this study open new therapeutic revenue for a debilitating disease with worst prognosis than that of lung cancer and fueled the first FDA-approved stem cell clinical trial in patients with IPF that is currently pending. The study was published in ***Journal of Translational Medicine 2013 Jul 15;11:171*, IF: 8.4, Citations: 171.**
5. **Major contributor and co-author in eight highly cited publications in the field of Pulmonary Fibrosis related to biomarkers and therapeutic targets. i) Implication of T-regulatory cells** **in the pathogenesis of IPF**. In this study we showed both numerical and functional impairment of T-regulatory cells in patients with IPF, reviving the role of immune deregulation in disease pathogenesis. Results were published in the ***Am J Respir Crit Care Med* 2009, IF: 30.5, Citations:149**. **ii)** Identification of gelsolin, an actin filament regulator as a therapeutic target in modeled lung fibrosis. The study was published in **Thorax *2009 Jun;64(6):467-75***. **IF:10.31, Citations:27,** and was followed by an editorial analysis, highlighting its significance in the research field of lung fibrosis. **iii) Identification of autotaxin as a major therapeutic target in lung fibrosis-** ***Am J Respir Cell Mol Biol. 2012 Nov;47(5):566-74*, IF: 6.9, Citations: 161.** Our seminal paper revealed for the first time in literature that autotaxin was upregulated in both experimental and human lung fibrosis and inhibition of autotaxin led to attenuation of experimental lung fibrosis. This paper led to a phase II and III RCT of safety and efficacy of an autotaxin inhibitor in patients with IPF**. iv)** I have also been a co-author in one of the most highly referenced papers the past 10 years in the research field of IPF. This study represents the first implication of **microRNAs** in the pathogenesis of lung fibrosis. Authors demonstrated that patients with IPF exhibit a distinct microRNA repertoire compared to controls and identified **let-7d and mir-29** as two of the most downregulated miRs within IPF lung. In vivo and in vitro experiments showed that TGFb downregulates let-7d while its inhibition in epithelial cells promoted epithelial mesenchymal transition. Results were published in the ***Am J Respir Crit Care Med* *2010 Jul 15;182(2):220-9*, IF:30.5, Citations:401)**. **v) I have also contributed** as middle co-author in a pivotal original contribution related to the identification of a **52-gene signature as disease prognosticator in 6 different cohorts of patients with IPF**, published in ***Lancet Respir Med. 2017 Nov;5(11):857-868*, IF: 102.6, Citations: 65, vi) In addition**, I have also contributed in first, middle and last author in several papers related to biomarkers of disease progressiveness and treatment responsiveness in patients with IPF, **including MMP-7 (*Respirology 2017 Apr;22(3):486-493.),* peripheral blood monocytes (*Respiratory Research 2021 May 5;22(1):140* and *Am J Respir Crit Care Med* *2021 Jul 1;204(1):74-81*) and mitochondrial DNA (*Am J Respir Crit Care Med* *2017 Dec 15;196(12):1571-1581*)**
6. **Major contributor in the field of concomitant lung fibrosis and cancer. First authorship and active participation in the design and handling of the first global survey (DIAMORFOSIS) related to the management of patients with concomitant IPF and lung cancer.** This was a joint-survey by European Respiratory Society (ERS) Assemblies 8, 11 and 12, consisted of 25 questions in which 494 physicians across the world participated and highlighted the need for a consensus statement. ERJ Open Research 2021 7: 00529-2020; **DOI:** 10.1183/23120541.00529-2020. With regards to lung cancer and pulmonary fibrosis, I exhibit 12 publications in Pubmed, including first authorship articles in major peer-reviewed journals such as : one commentary in ***Lancet Respir Med. 2018 Feb;6(2):86-88***. , one review article in ***Chest. 2019 Aug;156(2):383-391***. ,and one review article in ***Pulm Pharmacol Ther. 2017 Aug;45:1-10***, as well as two original contributions related to the incidence of lung cancer in more than 1000 patients with IPF in Greece- ***Pulm Pharmacol Ther. 2020 Feb;60:101880 and most recently in Respirology (in press).***

**B. Positions and Honors**

**Professional Experience**

Oct 2004 – Oct 2005 European Respiratory Society, Long Term Research Fellowship, Imperial College

 Royal Brompton Hospital, London, UK

Dec 2007 – May 2012 Internal Medicine Residency and Fellowship in Pulmonary, Critical Care and Sleep

 Medicine; Department of Pneumonology, Internal and Critical Care Medicine, Medical

 School, Democritus University of Thrace, Greece.

Mar 2009 – Jul 2011 Master (MSc) of Clinical Pharmacology and Therapeutics, Medical School, Democritus

 University of Thrace and Medical School, University of Crete, Greece

Sep 2012 HERMES Adult European Respiratory Diplomat

Sep 2012 – May 2013 Compulsory Military Service, Greece

Oct 2013 – May 2016 Postdoctoral Associate, Yale University School of Medicine, and Department of Internal

 Medicine, Section of Pulmonary, Critical Care & Sleep Medicine, New Haven CT

May 2016 – May 2018 Postdoctoral ERS/Marie Skłodowska-Curie Fellow, BSRC Alexander Fleming, Greece

January 2017 –present Consultant Respiratory Physician/Clinical Scholar, 1st Academic Department of Pneumonology, Hospital of ThoracicDiseases “Sotiria”, University of Athens, Greece

May 2018 Certificate in EBUS bronchoscopy

September 2018 - Associate Professor of Internal and Respiratory Medicine, University of Patras (elect)

October 2018 Certificate in Thoracic Imaging – European Respiratory Society Course

August 2019 - Associate Professor of Internal and Respiratory Medicine, University of Patras, Greece

May 2020 – Head of the Department of Respiratory Medicine, University Hospital of Patras, Greece

Jan 2021 - Associate Professor Adjunct, Pulmonary Critical Care and Sleep Medicine, Yale School of Medicine, USA

**Honors and Awards**

Oct 2004 Long Term Research Fellowship, European Respiratory Society, Imperial College Royal Brompton Hospital, London

Dec 2005 1st Award GlaxoSmithKline annual research grant, Title of project: “The role of angiogenesis in the pathogenesis of Idiopathic Interstitial Pneumonias”

Dec 2006 Bursary for the 5th International Lung Science ERS Conference, Taormina, Sicily

Sep 2007 ERS young scientist sponsorship, ERS congress, Stockholm

May 2008 American Thoracic Society, Public Advisory Roundtable, Allergy, Immunology and Inflammation, Award. ATS congress, Toronto

Oct 2008 Top 5% special abstract award, European Respiratory Society Conference, Berlin

Nov 2008 1st Award GlaxoSmithKline Annual Research Grant, Title of project: “The coagulation cascade in the pathogenesis of fibrotic lung disease. Study of the role of Tissue Factor (TF) in different forms of pulmonary fibrosis.”

Nov 2008 Best Project Award, Hellenic Thoracic Society Annual Congress. Title of abstract: “Role of gelsolin in the pathogenesis of pulmonary fibrosis”

Nov 2009 Best Presentation Award, Hellenic Thoracic Society Annual Congress Title of abstract: “Study of the inhibition and role of Let-7d in Idiopathic Pulmonary Fibrosis.”

Nov 2010 3rd unrestricted grant by Hellenic Thoracic Society, Title of project: “Study of the role of microRNAs (mir-409) in the pathogenesis of pulmonary fibrosis”

Nov 2011 1st unrestricted grant by Hellenic Thoracic Society, Title of project: “Study of the role of the adipose derived stem cells-stromal vascular fraction (SVF) in the treatment and pathogenesis of lung fibrosis”

Aug 2013 Oral Presentation Award, Session 6. Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Conference, University of Vermont, Burlington, VT. “A prospective, nonrandomized no placebo controlled phase Ib clinical trial to study the safety of the adipose derived stem cells in patients with Idiopathic Pulmonary Fibrosis”

May 2015 Best Poster Award, “ SHP2 is a novel anti-fibrotic agent in IPF” Yale Fibrosis Symposium

July 2015 American Lung Association Senior Research Training Fellowship, Title of Project: SHP-2 as a Novel Anti-Fibrotic Agent in IPF

April 2016 Joint Meeting Travel Award, American Association of Physicians Scientists for Best Poster titled: “SHP2 is a novel anti-fibrotic agent in IPF”

May 2016 European Respiratory Society/Marie Skłodowska-Curie/RESPIRE 2-Post-Doctoral Fellowship, Title of Project: The role of phosphatases as anti-fibrotic regulators of fibroblast homeostasis in pulmonary fibrosis

July 2016 American Lung Association Senior Research Training Fellowship, Title of Project: SHP-2 as a Novel Anti-Fibrotic Agent in IPF-***Declined***

January 2017 Scientific Research Award for Best Poster Presentation “Thyroid Hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells”, 4th International Workshop on Lung Health, Budapest 2017

March 2017 Distinguished Poster Award, ERS Lung Science Conference, “SHP-2 is a novel anti-fibrotic regulator of fibroblast homeostasis”.

November 2018 1st unrestricted grant by Hellenic Thoracic Society, Title of project: “SHP2 is a novel anti-fibrotic agent through regulation of fibroblast mitochondrial metabolism and autophagy”

**Participation in Pharmaceutical Clinical trials**

**Trial Role Year Sponsor**

1. MA29957 Sub-I 2017- Roche
2. MA39189 Sub-I 2017- Roche
3. INDULGE Sub-I 2016- BI
4. ARIES Sub-I 20010-12 GSK
5. TOMORROW Sub-I 2009-11 BI
6. PEGASUS Sub-I 2003-2005 Pfizer
7. COBRA Sub-I 2003-2005 Aventis
8. GCP CERTIFICATE 06/05/2020
9. BI1015550 PI 2021 BI
10. WA42293 PI 2021 ROCHE
11. WA 42294 PI 2021 ROCHE
12. 1199-0355 PI 2021 BI
13. 2020-BUDFOR-EL-127 PI 2021 ΕΛΠΕΝ
14. D5982C00008(LOGOS) PI 2021 ASTRAZENECA
15. 1305-0013 PI 2021 BI
16. MISTIC PI 2022 CHIESI
17. 1397-0012 PI 2022 BI
18. MeGR/20/COPD-NIS/001 PI 2022 MENARINI
19. HZNP-HZN-825-303 PI 2022 PPD
20. D9180C00004 (TITANIA) PI 2022 ASTRAZENECA
21. PHOLLOW PI 2022 ASTRAZENECA
22. 1305-0023  PI 2022 BI

**1) Total Number of Publications: 271 Scopus (254 in PubMed),**

**2) Original peer-reviewed articles: 93**

**3) First and last author (total articles): 109**

**4) H-index: 48 (Scopus),**

**5) Total citations: 7713 (Scopus)**

**6) Mean Impact Factor: 11.14**

**7) Total Impact Factor: 2352.4**

**Publications (Peer-Reviewed) (from a total of 267)**

1. **Tzouvelekis A,** Harokopos V, Paparountas P, Oikonomou N, Hatziioannou A, Karameris A, Tsiambas E, Vilaras G, Bouros D and Aidinis V. Comparative expression profiling and meta-analysis in pulmonary fibrosis suggests an early role of Hypoxia inducible factor 1 in disease pathogenesis. ***Am J Respir Crit Care Med* 2007;** 176(11):1108-19. PMID:17761615
2. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tzouvelekis%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus)**,** [Aidinis V](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Aidinis%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Harokopos V](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Harokopos%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Karameris A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Karameris%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Zacharis G](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Zacharis%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Mikroulis D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mikroulis%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Konstantinou F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Konstantinou%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Steiropoulos P](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Steiropoulos%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Sotiriou I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sotiriou%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Froudarakis M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Froudarakis%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Pneumatikos I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pneumatikos%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Tringidou R](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tringidou%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Bouros D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bouros%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. ***Respir Res.*** **2009**;10:14. PMID:19250543; PMCID:PMC2662808
3. [Kotsianidis I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kotsianidis%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Nakou E](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nakou%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Bouchliou I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bouchliou%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tzouvelekis%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus)**,** [Spanoudakis E](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Spanoudakis%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Steiropoulos P](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Steiropoulos%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Sotiriou I](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sotiriou%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Aidinis V](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Aidinis%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Margaritis D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Margaritis%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Tsatalas C](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tsatalas%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Bouros D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bouros%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. ***Am J Respir Crit Care Med.*** **2009**;179(12):1121-30. PMID:19342412
4. Oikonomou N, Thanasopoulou A, **Tzouvelekis A,** Harokopos V, Paparountas T, Nikitopoulou I, Witke W, Karameris A, Kotanidou A, Bouros D and Aidinis V. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. ***Thorax***. **2009**;64(6):467-75. PMID:19213772
5. [Pandit KV](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pandit%20KV%22%5BAuthor%5D), [Corcoran D](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Corcoran%20D%22%5BAuthor%5D), [Yousef H](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yousef%20H%22%5BAuthor%5D), [Yarlagadda M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yarlagadda%20M%22%5BAuthor%5D), [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tzouvelekis%20A%22%5BAuthor%5D)**,** [Gibson KF](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gibson%20KF%22%5BAuthor%5D), [Konishi K](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Konishi%20K%22%5BAuthor%5D), [Yousem SA](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yousem%20SA%22%5BAuthor%5D), [Singh M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Singh%20M%22%5BAuthor%5D), [Handley D](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Handley%20D%22%5BAuthor%5D), [Richards T](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Richards%20T%22%5BAuthor%5D), [Selman M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Selman%20M%22%5BAuthor%5D), [Watkins SC](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Watkins%20SC%22%5BAuthor%5D), [Pardo A](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pardo%20A%22%5BAuthor%5D), [Ben-Yehudah A](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ben-Yehudah%20A%22%5BAuthor%5D), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bouros%20D%22%5BAuthor%5D), [Eickelberg O](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Eickelberg%20O%22%5BAuthor%5D), [Ray P](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ray%20P%22%5BAuthor%5D), [Benos PV](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Benos%20PV%22%5BAuthor%5D), [Kaminski N](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kaminski%20N%22%5BAuthor%5D). Inhibition and Role of Let-7d in Idiopathic Pulmonary Fibrosis. ***Am J Respir Crit Care Med.*** **2010**;182 (2):220-9. PMID:20395557; PMCID:PMC2913236
6. [Oikonomou N](http://www.ncbi.nlm.nih.gov/pubmed?term=Oikonomou%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Mouratis MA](http://www.ncbi.nlm.nih.gov/pubmed?term=Mouratis%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22744859)**,** [Kaffe E](http://www.ncbi.nlm.nih.gov/pubmed?term=Kaffe%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Valavanis C](http://www.ncbi.nlm.nih.gov/pubmed?term=Valavanis%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Vilaras G](http://www.ncbi.nlm.nih.gov/pubmed?term=Vilaras%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Karameris A](http://www.ncbi.nlm.nih.gov/pubmed?term=Karameris%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Prestwich GD](http://www.ncbi.nlm.nih.gov/pubmed?term=Prestwich%20GD%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22744859), [Aidinis V](http://www.ncbi.nlm.nih.gov/pubmed?term=Aidinis%20V%5BAuthor%5D&cauthor=true&cauthor_uid=22744859). Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. [***Am J Respir Cell Mol Biol.***](http://www.ncbi.nlm.nih.gov/pubmed/22744859) **2012**;47(5):566-74. PMID:22744859
7. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22855473)**,** [Zacharis G](http://www.ncbi.nlm.nih.gov/pubmed?term=Zacharis%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22855473), [Oikonomou A](http://www.ncbi.nlm.nih.gov/pubmed?term=Oikonomou%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22855473), [Koulelidis A](http://www.ncbi.nlm.nih.gov/pubmed?term=Koulelidis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22855473), [Steiropoulos P](http://www.ncbi.nlm.nih.gov/pubmed?term=Steiropoulos%20P%5BAuthor%5D&cauthor=true&cauthor_uid=22855473), [Froudarakis M](http://www.ncbi.nlm.nih.gov/pubmed?term=Froudarakis%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22855473), [Kriki P](http://www.ncbi.nlm.nih.gov/pubmed?term=Kriki%20P%5BAuthor%5D&cauthor=true&cauthor_uid=22855473), [Vargemezis V](http://www.ncbi.nlm.nih.gov/pubmed?term=Vargemezis%20V%5BAuthor%5D&cauthor=true&cauthor_uid=22855473), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22855473). Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. [**Eur Respir J.**](http://www.ncbi.nlm.nih.gov/pubmed/22855473) **2012 Aug;40(2):505-7**
8. [**Tzouvelekis A**](http://www.ncbi.nlm.nih.gov/pubmed?term=Tzouvelekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653)**,** [Paspaliaris V](http://www.ncbi.nlm.nih.gov/pubmed?term=Paspaliaris%20V%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Koliakos G](http://www.ncbi.nlm.nih.gov/pubmed?term=Koliakos%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Ntolios P](http://www.ncbi.nlm.nih.gov/pubmed?term=Ntolios%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Bouros E](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Oikonomou A](http://www.ncbi.nlm.nih.gov/pubmed?term=Oikonomou%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Zissimopoulos A](http://www.ncbi.nlm.nih.gov/pubmed?term=Zissimopoulos%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Boussios N](http://www.ncbi.nlm.nih.gov/pubmed?term=Boussios%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Dardzinski B](http://www.ncbi.nlm.nih.gov/pubmed?term=Dardzinski%20B%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Gritzalis D](http://www.ncbi.nlm.nih.gov/pubmed?term=Gritzalis%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Antoniadis A](http://www.ncbi.nlm.nih.gov/pubmed?term=Antoniadis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Froudarakis M](http://www.ncbi.nlm.nih.gov/pubmed?term=Froudarakis%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Kolios G](http://www.ncbi.nlm.nih.gov/pubmed?term=Kolios%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23855653), [Bouros D](http://www.ncbi.nlm.nih.gov/pubmed?term=Bouros%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23855653). A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. [***J Transl Med*.**](http://www.ncbi.nlm.nih.gov/pubmed/23855653) **2013** ;11(1):171. PMID:23855653; PMCID:PMC3722100
9. **Tzouvelekis A,** Bouros D. Anti-acid treatment for idiopathic pulmonary fibrosis. ***Lancet Respir Med*.** **2013**;1(5):348-9. PMID:24429187
10. Bouros D, **Tzouvelekis A.** Idiopathic Pulmonary Fibrosis: On the move. ***Lancet Respir Med.* 2014**;2(1):17-9. PMID:24461889
11. **Tzouvelekis A,** Guyoing Yu, Jose Herazo-maya, Naftali Kaminski et al. SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in Pulmonary Fibrosis. ***Am J Respir Crit Care Med* 2016** 2017;195(4):500-514. PMID: 27736153
12. Guoying Yu\*, **Argyrios Tzouvelekis\*,** , Gabriel Ibarra, Rong Wang, Jose D. Herazo-Maya,Anup Srivastava, Joao Pedro Werneck de Castro, Giuseppe DeIuliis, Farida Ahangari, Tony Woolard, Nachelle Aurelien, Rafael Arrojo e Drigo , Robert Homer, Ye Gan, Morven Graham, Xinran Liu, Praveen Mannam, Patty J. Lee, Erica L. Herzog, Antonio C. Bianco, Naftali Kaminski. **Thyroid hormone inhibits fibrosis and improves epithelial mitochondrial function in experimental pulmonary fibrosis.Nat Med. 2017 Dec 4. doi: 10.1038/nm.4447.**
13. Jose D. Herazo-Maya, Jiehuan Sun, Philip Molyneaux, Julian Villalba-Nunez, **Argyrios Tzouvelekis**, Erica L. Herzog, Naftali Kaminski. A 52-gene signature in peripheral blood identifies a genomic profile associated with increased risk of mortality and poor disease outcomes in Idiopathic Pulmonary Fibrosis. ***Lancet Respir Med* 2017** Sep 20. pii: S2213-2600(17)30349-1. doi: 10.1016/S2213-2600(17)30349-1
14. Changwan Ryu, Huanxing Sun, Mridu Gulati, Jose D. Herazo-Maya, Yonglin Chen, Awo Osafo-Addo, Caitlin Brandsdorfer, Julia Winkler, Christina Blaul, Jaden Faunce, Hongyi Pan, Tony Woolard, **Argyrios Tzouvelekis,** Danielle E. Antin-Ozerkis, Jonathan T. Puchalski, Zheng Wu,Naftali Kaminski, Erica Herzog, Glenda Trujillo.Extracellular Mitochondrial DNA is generated by fibroblasts and predicts death in Idiopathic Pulmonary Fibrosis. ***Am J Respir Crit Care Med 2017*** *Aug 7. doi: 10.1164/rccm.201612-2480OC. [Epub ahead of print]*
15. **Tzouvelekis A**, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, Bouros D. [Patients with IPF and lung cancer: diagnosis and management.](https://www.ncbi.nlm.nih.gov/pubmed/29241977) **Lancet Respir Med. 2017 Dec 11. pii: S2213-2600(17)30478-2. doi: 10.1016/S2213-2600(17)30478-2.**

**D. Teaching/Administrative experience**

1. **Member of teaching committee** of the Master of Sciences **(MSc)** titled: **Sleep Medicine**, Democritus University of Thrace, Greece. **Period: April 2017 - ongoing**
2. **Member of teaching committee** of the Master of Sciences **(MSc)** titled: **Clinical Pharmacology and Therapeutics,** Democritus University of Thrace, Greece. **Period: May 2017 – ongoing**
3. **Scientific Lecture at the** Master of Sciences **(MSc)** titled: **Clinical Pharmacology and Therapeutics,** Democritus University of Thrace, Greece.
4. Scientific Lectures at **First Academic Department of Pneumonology,** General Hospital of Thoracic Diseases “SOTIRIA”, **University of Athens, Greece. Period: January 2017 - ongoing**
5. Supervisor of 9 undergraduate students, 2 PhD students. **Biomedical Sciences Research Center “Alexander Fleming”,** Athens, Greece: **Period: May 2016 - ongoing**
6. **Supervisor** of 2 post-graduate, 1 PhD and 2 post-doctoral students. **Yale School of Medicine**, CT, USA. **Period: October May 2014 - May 2016**
7. **Scientific Lectures (n=3) at Post-Graduate Seminars in ILDs. Period 2013-2017**
8. **Member of the ERS College of Experts**
9. **Member of the ERS RESPIRE mentoring scheme**

**E. Research Support**

**Completed Research Support (last 7 years)**

ERS/Marie Skłodowska-Curie Postdoctoral Research Fellowship 30/4/2016 – 30/4/2018

RESPIRE2 3rd round/Proposal No: 8860-2015

**The role of phosphatases as anti-fibrotic regulators of fibroblast homeostasis in pulmonary fibrosis**

The overall objective is to understand the mechanisms of SHP-2 action within the fibrotic lung and determine whether SHP-2 could serve as a therapeutic target in IPF.

Role: Senior Post-Doc

UH2 HL123886-01 (Kaminski) 7/1/14 – 6/30/19

NIH / NHLBI

**Mir-29 Mimicry as a Therapy for Pulmonary Fibrosis**

The overall objective of this proposal is to develop miR-29 mimicry as a long-term, efficient and personalized anti-fibrotic therapy. The rationale for this proposal stems from the significant body of work that indicates the important anti-fibrotic role of miR-29 in fibrosis, the efficacy of the mirage miR-29 mimic and the likelihood of identifying a high risk IPF patient population likely to benefit from miR-29 supplementation.

Role: Postdoctoral Associate

Biogen Idec, Inc (Kaminski) 7/1/14 – 6/30/16

**Molecular Phenotyping of Disease Relevant Cell Populations in IPF**

The focus of this research project is to carry out molecular phenotyping of disease relevant cell populations in IPF lungs.

Role: Postdoctoral Associate

U01 (Benos / University of Pittsburgh) 7/1/14 – 6/30/18

NIH / NHLBI

**Center for Casual Modeling and Discovery of Biomedical Knowledge from Big Data**

In this grant, we propose to capitalize on the publicly available and private data from the Lung Genomics Research Consortium (LGRC) and Lung Tissue Research Consortium (LTRC) resources to develop the software and tools to identify causal relationships between (1) omic data and image features and (2) disease characteristics and subtypes

Role: Postdoctoral Associate

Senior Research Training Fellowship/Proposal No: RT-350419 7/1/2015 – 7/12016

American Lung Association

**SHP-2 as a Novel Anti-Fibrotic Agent in IPF**

The overall objective is to understand the mechanisms of SHP-2 action within the fibrotic lung and determine whether SHP-2 could serve as a therapeutic target in IPF.

Role: Senior Post-Doc

Hellenic Thoracic Society (Tzouvelekis) 11/1/2011 – 11/1/2013

Unrestricted Research Grant

**Study of the role of the adipose derived stem cells-stromal vascular fraction (SVF) in the treatment and pathogenesis of lung fibrosis**

Goals: Study the effects of three endobronchial infusions of autologous adipose-derived stem cells-stromal vascular fraction in patients with mild-to-moderate Idiopathic Pulmonary Fibrosis in the context of a non-randomized no placebo-controlled phase Ib clinical trial in 1) incidence of treatment emergent adverse events (safety-primary end-point), 2) functional, exercise capacity and quality of life parameters (efficacy-secondary end-points)

Role: PI

The Godrej Group, India (Tzouvelekis) 9/1/2011 – 9/1/2013

Unrestricted Research Grant

**Study of the role of the adipose derived stem cells-stromal vascular fraction (SVF) in the treatment and pathogenesis of lung fibrosis**

Goals: Study the effects of three endobronchial infusions of autologous adipose-derived stem cells-stromal vascular fraction in patients with mild-to-moderate Idiopathic Pulmonary Fibrosis in the context of a non-randomized no placebo-controlled phase Ib clinical trial in 1) incidence of treatment emergent adverse events (safety-primary end-point), 2) functional, exercise capacity and quality of life parameters (efficacy-secondary end-points)

Role: PI

**E. Member of Scientific Societies:** Hellenic Thoracic, European Respiratory and American Thoracic Society and ICLAF (International Colloquium of Lung and Airway Fibrosis)

 280625